title: Quetiapine dosage in bipolar disorder episodes and mixed states.
abstract: OBJECTIVE
  Although the maximal quetiapine doses in the published studies were restricted to 800 mg/day, higher quetiapine doses are not unusual in clinical practice. The aim of the present study was to evaluate the effectiveness, tolerability and clinical reasons associated to the use of high dosage of quetiapine (>800 mg), when used under routine clinical conditions, in a sample of bipolar disorder and schizoaffective bipolar inpatients.
  
  
  METHODS
  Charts of all bipolar and schizoaffective adult inpatients, who had received quetiapine for a mood episode between 1999 and 2005 were retrospectively reviewed. These charts also included the assessment of manic and depressive symptoms on admission and at discharge using the Beck-Rafaelsen Mania Scale (MAS) and the Montgomery Asberg depression rating scale (MADRS), respectively.
  
  
  RESULTS
  Data of 50 patients were analyzed. The overall F in repeated measures ANOVA revealed a significant MAS scores reduction between admission and discharge. MAS scores reduction did not differ between the high and low quetiapine groups. Similarly, a significant MADRS reduction was found. Again, no differences between the high and the low dose group were found. Logistic regression analysis of the 50 patients revealed only mixed episodes predicted high quetiapine dosage.
  
  
  CONCLUSIONS
  The present study confirms quetiapine efficiency and tolerability in the treatment of bipolar episodes, even in doses > to 800 mg and found a link between quetiapine doses and mixed episodes.
authors.affiliation: Department of Psychiatry, University Hospital of Vaud, Lausanne, Switzerland. yasser.hkazzal@chuv.ch
authors.forename: Yasser
authors.initials: Y
authors.lastname: Khazaal
authors.forename: Sophie
authors.initials: S
authors.lastname: Tapparel
authors.forename: Anne
authors.initials: A
authors.lastname: Chatton
authors.forename: Stephane
authors.initials: S
authors.lastname: Rothen
authors.forename: Martin
authors.initials: M
authors.lastname: Preisig
authors.forename: Daniele
authors.initials: D
authors.lastname: Zullino
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D010054:Brief Psychiatric Rating Scale; D003987:Dibenzothiazepines / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069348:Quetiapine Fumarate; D012189:Retrospective Studies
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate